New Dual-Antibody combo tackles multiple advanced cancers in early trial
NCT ID NCT05858736
First seen Apr 10, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This early-stage trial is testing a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with various advanced solid tumors that have spread or come back. The main goals are to find a safe dose and watch for side effects, with early signs of tumor shrinkage also being tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Research SA
Adelaide, South Australia, 5000, Australia
-
Mater Misericordiae Ltd.
Brisbane, Queensland, 4006, Australia
-
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, 5042, Australia
-
St. Vincent's Private Hospital
Darlinghurst, New South Wales, 2010, Australia
-
Tasman Oncology Research
Southport, Queensland, 4120, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-061 (a combination of two antibodies: anti-PD-1 and anti-CTLA-4)
What this could lead to
If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 18 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects like immune-related inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.